Tenaya Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-90.6M | $-111.1M | $-124.1M | $-123.7M | $-72.7M | $-38.4M |
| Depreciation & Amortization | $8.4M | $8.5M | $8.7M | $6.5M | $3.0M | $2.5M |
| Depreciation | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $13.0M | $16.5M | $15.3M | $11.5M | $3.0M | $741.0K |
| Net Cash from Operating Activities | $-68.3M | $-90.5M | $-102.1M | $-104.4M | $-60.8M | $-35.4M |
| Investing Activities | ||||||
| Capital Expenditures | $618.0K | $1.0M | $1.2M | $20.6M | $25.1M | $9.8M |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $56.1M | $1.1M | $48.7M | $83.7M | $-238.6M | $-7.0M |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | $13.0K | $1.0K |
| Net Cash from Financing Activities | $108.4M | $47.7M | $4.0M | $77.8M | $209.0M | $147.3M |
| Net Change in Cash | $96.2M | $-41.6M | $-49.3M | $57.0M | $-90.4M | $104.8M |
| Free Cash Flow | $-68.9M | $-91.5M | $-103.3M | $-125.1M | $-85.9M | $-45.2M |